apixaban

Apixaban, Warfarin Equally Safe, Study FindsA study found that apixaban is a safe alternative to VKAs for ablation of atrial fibrillation.
Fall-related ICH incidence in elderly on warfarinA study of nearly 32,000 aging veterans revealed the unsuspected vulnerability of this population.
Andexanet quickly reverses factor Xa inhibitor activity for DOACsAndexanet alpha is designed to reverse the anticoagulant effects of factor Xa inhibitors.
Rivaroxaban for inherited thrombophilia: A case studyIs rivaroxaban the best therapeutic option for this patient?
New data: Hospital readmission among NVAF hospitalized patients treated with new oral anticoagulantsData from a real-world analysis provided an early view of hospital readmissions among hospitalized nonvalvular atrial fibrillation (NVAF) patients treated with new oral anticoagulants (NOACs).
ACC: NVAF patients at high risk for stroke may be undertreatedMany nonvalvular atrial fibrillation (NVAF) patients at high risk for stroke may be undertreated, according to poster presentation sessions at the American College of Cardiology (ACC) 64th Annual Scientific Session in San Diego, Calif.
Aspirin fails in Japanese primary prevention studyIf patients have multiple risk factors, daily low-dose aspirin may not make much difference to their potential for CV events.
Study evaluates use of novel oral anticoagulants in ICUApproximately one-third of patients on a novel oral anticoagulant (NOAC) received inappropriate dosing based on indication, renal function, or concomitant interacting medications during hospitalization in the intensive care unit, typically for stroke prevention in atrial fibrillation, according to data presented at the Society of Critical Care Medicine meeting in Phoenix.
NSAIDs increase bleeding risk in patients taking anticoagulantsA Danish study of 150,900 patients found that the risk of serious bleeding doubled when patients were treated with NSAIDs.
What is new in the anticoagulant antidote market?The use of new oral anticoagulants (NOACs) continues to increase. Over the past 4 quarters, rivaroxaban (Xarelto, Bayer/Johnson & Johnson) and apixaban (Eliquis, Bristol-Myers Squibb/Pfizer) were in the top 20 of fastest-growing drugs in the United States. They offer advantages compared to warfarin such as a rapid onset of action, no dietary modifications, fewer drug–drug interactions, and do not require routine coagulation monitoring.